R
Richard E. Champlin
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1500
Citations - 73470
Richard E. Champlin is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 138, co-authored 1402 publications receiving 66917 citations.
Papers
More filters
Journal ArticleDOI
Impact of Donor Type and Melphalan Dose on Allogeneic Transplantation Outcomes for Patients with Lymphoma.
Neeraj Saini,Rima M. Saliba,Gabriela Rondon,Farzaneh Maadani,Uday R. Popat,Chitra Hosing,Betul Oran,Qaiser Bashir,Amanda Olson,Yago Nieto,Amin M. Alousi,Partow Kebriaei,Samer A. Srour,Rohtesh S. Mehta,Paolo Anderlini,Elizabeth J. Shpall,Muzaffar H. Qazilbash,Issa F. Khouri,Luis Fayad,Hun Lee,Nathan Fowler,Simrit Parmar,Jason R. Westin,Fredrick B. Hagemeister,Richard E. Champlin,Stefan O. Ciurea +25 more
TL;DR: In patients with lymphoma, ASCT with HD transplants have similar outcomes as AsCT with HLA-matched transplants, and the FM100 conditioning regimen appears to be at least as effective as the FM140 regimen.
Journal ArticleDOI
Patient age and number of apheresis days may predict development of secondary myelodysplastic syndrome and acute myelogenous leukemia after high-dose chemotherapy and autologous stem cell transplantation for lymphoma.
Isabell Ge,Rima M. Saliba,Farzaneh Maadani,Uday R. Popat,Muzaffar H. Qazilbash,Sai Ravi Pingali,Nina Shah,Sairah Ahmed,Qaiser Bashir,Yago Nieto,Richard E. Champlin,Chitra Hosing +11 more
TL;DR: The goal of this study was to find predictors for the development of secondary myelodysplastic syndrome or acute myelogenous leukemia in patients with relapsed or refractory lymphoma who received high‐dose chemotherapy and autologous stem cell transplantation (ASCT).
Journal ArticleDOI
High-dose chemotherapy and autologous peripheral blood stem cell transplantation for primary breast cancer refractory to neoadjuvant chemotherapy.
Naoto T. Ueno,Sergej Konoplev,Thomas A. Buchholz,Terry K. Smith,Gabriella Rondon,Paolo Anderlini,Sergio Giralt,James Gajewski,M. Donato,Massimo Cristofanilli,Richard E. Champlin +10 more
TL;DR: Both OS and PFS were better in patients whose disease became operable after chemotherapy than in those whose disease remained inoperable.
Journal ArticleDOI
Allogeneic stem cell transplant for patients with myeloproliferative neoplasms in blast phase: improving outcomes in the recent era.
Mithun Vinod Shah,Rima M. Saliba,Ankur Varma,Stefan O. Ciurea,Betul Oran,Amanda Olson,Prithviraj Bose,Qaiser Bashir,Lucia Masarova,Amin M. Alousi,Samer A. Srour,Rohtesh S. Mehta,Naval Daver,Naveen Pemmaraju,Srdan Verstovsek,Richard E. Champlin,Uday R. Popat +16 more
Journal ArticleDOI
Long-Term Follow-up of the Combination of Low-Intensity Chemotherapy Plus Inotuzumab Ozogamicin with or without Blinatumomab in Patients with Relapsed-Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Trial
Koji Sasaki,Hagop M. Kantarjian,Farhad Ravandi,Nicholas J. Short,Partow Kebriaei,Xuelin Huang,Nitin Jain,Marina Konopleva,Guillermo Garcia-Manero,Richard E. Champlin,Tapan M. Kadia,Koichi Takahashi,Naval Daver,Hind Rafei,Joseph D. Khoury,Jeffrey L. Jorgensen,Sa A. Wang,Maria Khouri,Jovitta Jacob,Rebecca Garris,Susan O'Brien,Elias Jabbour +21 more
TL;DR: The combination of inotuzumab with low-intensity mini-hyper-CVD chemotherapy showed encouraging results in this patient population, and the sequential addition of blinatumomab might optimize the efficacy of the regimen, reduce its toxicities, and further improve outcomes in R-R ALL.